Dropropizine

Summary

Dropropizine (CHEMBL151445) is a phase-3 clinical-stage small molecule (ATC R05DB19); indicated across 3 conditions including rhinitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: R05DB19
• Indications: 3 conditions
• Clinical trials: 5
• Chemistry: 236.31 Da · C13H20N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL151445
Name	Dropropizine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3169
ATC	R05DB19
Molecular formula	C13H20N2O2
Molecular weight	236.31
InChIKey	PTVWPYVOOKLBCG-UHFFFAOYSA-N

SMILES: C1CN(CCN1CC(CO)O)C2=CC=CC=C2

IUPAC name: 3-(4-phenylpiperazin-1-yl)propane-1,2-diol

Also known as: Catabex, Dipropizine, Ditustat, Dopropizin, Dropropizina, Dropropizine, Katril, Larylin, NSC-757820, Ribex, Tussilex, U.C.B.-1967

Patent coverage: 218 distinct patent families (652 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rhinitis	3	MONDO:0003014	EFO:0008521

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE4	1
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06907355	PHASE4	COMPLETED	CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS
NCT01177852	PHASE3	WITHDRAWN	Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
NCT01416480	PHASE3	COMPLETED	Clinical Trial to Evaluate the Safety and Efficacy of Theobromine Capsule as an Antitussive in Acute Cougher
NCT06252454	PHASE2/PHASE3	UNKNOWN	The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases
NCT01573663	PHASE1	COMPLETED	A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).